Recent Updates
Recently added Catalysts
NRIX Positive Sentiment Score: 70/100

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Key Takeaway: Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced its participation in two significant investor conferences in September, including the Wells Fargo and Baird Global Healthcare Conferences. CEO Arthur T. Sands will represent the company in a series of fireside chats at these events. These conferences will provide a platform for Nurix to enhance its visibility and discuss its innovative therapies focused on treating cancer. The webcasts of the events will be available for approximately 30 days thereafter on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Upcoming participation in major investor conferences enhances visibility.
  • Prominent leadership representation by CEO Arthur T. Sands.
  • Focus on innovative therapies for hematologic malignancies and solid tumors.

Full Press Release Details

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer will participate in the following conferences in September:
Wells Fargo Healthcare Conference
Fireside chat: Thursday, September 7, 3:00 – 3:45 p.m. ET
Baird Global Healthcare Conference
Fireside chat: Tuesday, September 12, 12:15 – 12:45 p.m. ET
The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. Archived copies of the webcasts will be available on the Nurix website for approximately 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of medicines based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
Wheelhouse Life Science Advisors

Frequently Asked Questions

What are the upcoming conferences for Nurix Therapeutics?

Nurix Therapeutics will participate in the Wells Fargo and Baird Global Healthcare Conferences in September.

Who is speaking at the Nurix conferences?

Arthur T. Sands, M.D., Ph.D., the CEO of Nurix Therapeutics, will speak.

How can I access the conference webcasts?

The webcasts can be accessed via the Investors section of Nurix's website.

What is Nurix Therapeutics focused on?

Nurix Therapeutics specializes in developing targeted protein modulation drugs for cancer.

Where is Nurix Therapeutics located?

Nurix Therapeutics is headquartered in San Francisco, California.

Last updated: Aug 31, 2023